Header5

The simple corporate scheme behind massive US Brand Drug Prices

My 7-year whistleblower effort
"People Before Profits"

U.S. Multiple Sclerosis Market: Most Extreme Pricing Abuse

Uniform 10-fold U.S. Price Increases for Numerous Plummeting Brands

U.S. Multiple Sclerosis (MS) Market:

  • Uniform massive U.S. brand price increases in the U.S. MS category from $15,000 to $100,000 per patient/year since Medicare Part D
  • Massive U.S. MS drug price increases despite severe competition and many new similar brand and generic drugs reaching the U.S. market over the past decade-plus
  • MASSIVE PRICE INCREASES FOR "OLD" U.S. MS BRAND DRUGS DESPITE PLUMMETING USE AND MARKET SHARE
    • Not possible in a legitimate U.S competitive marketplace
    • Massive "old"' brand increases fueled more pricing abuse with numerous similar new U.S. MS brand drugs reaching the market
  • More than $60 billion in abusive U.S. MS drug costs over the past decade-plus for the eight (8) whistleblower case brand drugs

Specific U.S. MS Brand Drugs:

Biogen’s Avonex (on U.S. market since 1996)

  • 2005 Reported U.S. Sales: $939 million
  • 2017 Reported U.S. Sales: $1.9 billion
  • U.S. Clinical Use/Prescriptions DOWN 60-70% since 2005
  • 2017 U.S. Sales WITHOUT Price Increases: $322 million
  • 2005 U.S. “List”/“Sticker” Price: $15,000/patient/year
  • 2018 U.S. “List”/“Sticker” Price: $98,000/patient/year
  • Cumulative harm since start of Part D: $12.5+ billion

Teva’s Copaxone (on U.S. market since 1996)

  • 2005 Reported U.S. Sales: $782 million
  • 2017 Reported U.S. Sales: $3.0 billion
  • U.S. Clinical Use/Prescriptions DOWN -40-50% since 2005
  • 2017 U.S. Sales WITHOUT Price Increases: $530 million
  • 2005 U.S. “List”/“Sticker” Price: $15,000/patient/year
  • 2018 U.S. “List”/“Sticker” Price: $90-100,000/patient/year
  • Cumulative harm since start of Part D: $20 billion

Pfizer/EMD Serono's Rebif (on U.S. market since 2002)

  • 2005 Reported U.S. Sales: $390 million
  • 2017 Reported U.S. Sales: $1.26 billion
  • U.S. Clinical Use/Prescriptions DOWN -45% since 2005
  • 2017 U.S. Sales WITHOUT Price Increases: $216 million
  • 2005 U.S. “List”/“Sticker” Price: $15,000/patient/year
  • 2018 U.S. “List”/“Sticker” Price: $99,000/patient/year
  • Cumulative harm since start of Part D: $8.4 billion

Bayer's Betaseron (on U.S. market since 1993)

  • 2005 Reported U.S. Sales: $584 million
  • 2017 Reported U.S. Sales: $482 million
  • U.S. Clinical Use/Prescriptions DOWN -80% since 2005
  • 2017 U.S. Sales WITHOUT Price Increases: $77 million
  • 2005 U.S. “List”/“Sticker” Price: $15,000/patient/year
  • 2018 U.S. “List”/“Sticker” Price: $103,000/patient/year
  • Cumulative harm since start of Part D: $4.6 billion

Receive the Latest News

Your email is 100% safe.
Your privacy will be respected.
!
!
Something went wrong. Please check your entries and try again.
Scroll to Top